{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:11:50Z","timestamp":1788361910546,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.phrs.2011.11.017","type":"journal-article","created":{"date-parts":[[2011,12,10]],"date-time":"2011-12-10T05:49:55Z","timestamp":1323496195000},"page":"312-319","source":"Crossref","is-referenced-by-count":22,"title":["Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone"],"prefix":"10.1016","volume":"65","author":[{"given":"Jakub","family":"Hofman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davoud","family":"Ahmadimoghaddam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Hahnova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Pavek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Ceckova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frantisek","family":"Staud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2011.11.017_bib0005","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/nrm2510","article-title":"Cyclin-dependent kinases and cell-cycle transitions: does one fit all?","volume":"9","author":"Hochegger","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.phrs.2011.11.017_bib0010","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1200\/JCO.2005.03.7689","article-title":"Cyclin-dependent kinase pathways as targets for cancer treatment","volume":"24","author":"Shapiro","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phrs.2011.11.017_bib0015","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2174\/138945010790711950","article-title":"Cyclin-dependent kinase inhibitors as anticancer drugs","volume":"11","author":"Krystof","year":"2010","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.phrs.2011.11.017_bib0020","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2174\/138945010790711978","article-title":"CDK inhibitors: from the bench to clinical trials","volume":"11","author":"Rizzolio","year":"2010","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.phrs.2011.11.017_bib0025","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1432-1033.1994.00771.x","article-title":"Inhibition of cyclin-dependent kinases by purine analogues","volume":"224","author":"Vesely","year":"1994","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.phrs.2011.11.017_bib0030","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1021\/ar0201198","article-title":"Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials","volume":"36","author":"Meijer","year":"2003","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.phrs.2011.11.017_bib0035","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.biocel.2004.11.004","article-title":"Breast cancer resistance protein (BCRP\/ABCG2)","volume":"37","author":"Staud","year":"2005","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.phrs.2011.11.017_bib0040","first-page":"237","article-title":"Chemotherapy-induced resistance by ATP-binding cassette transporter genes","volume":"1775","author":"Gillet","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.phrs.2011.11.017_bib0045","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2174\/092986707780059580","article-title":"Human multidrug transporter ABCG2, a target for sensitizing drug resistance in cancer chemotherapy","volume":"14","author":"Xu","year":"2007","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.phrs.2011.11.017_bib0050","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/sj.bjp.0707218","article-title":"The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2)","volume":"151","author":"Hardwick","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.phrs.2011.11.017_bib0055","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1124\/jpet.104.073916","article-title":"Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine","volume":"312","author":"Pavek","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.phrs.2011.11.017_bib0060","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1528-1167.2006.00453.x","article-title":"Lack of interactions between breast cancer resistance protein (bcrp\/abcg2) and selected antiepileptic agents","volume":"47","author":"Cerveny","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2011.11.017_bib0065","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1124\/jpet.109.160564","article-title":"Transplacental pharmacokinetics of glyburide, rhodamine 123, and BODIPY FL prazosin: effect of drug efflux transporters and lipid solubility","volume":"331","author":"Cygalova","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.phrs.2011.11.017_bib0070","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"10.1016\/j.phrs.2011.11.017_bib0075","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.phrs.2011.11.017_bib0080","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood.V99.2.507","article-title":"The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors","volume":"99","author":"Scharenberg","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2011.11.017_bib0085","first-page":"47","article-title":"Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein","volume":"60","author":"Rabindran","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.phrs.2011.11.017_bib0090","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.placenta.2005.11.012","article-title":"Transport of glyburide by placental ABC transporters: implications in fetal drug exposure","volume":"27","author":"Gedeon","year":"2006","journal-title":"Placenta"},{"issue":"Pt 11","key":"10.1016\/j.phrs.2011.11.017_bib0095","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1242\/jcs.113.11.2011","article-title":"The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2)","volume":"113","author":"Litman","year":"2000","journal-title":"J Cell Sci"},{"key":"10.1016\/j.phrs.2011.11.017_bib0100","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1440-1681.2006.04324.x","article-title":"Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo","volume":"33","author":"Ceckova","year":"2006","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.phrs.2011.11.017_bib0105","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11596-007-0217-8","article-title":"The roles of four multi-drug resistance proteins in hepatocellular carcinoma multidrug resistance","volume":"27","author":"Li","year":"2007","journal-title":"J Huazhong Univ Sci Technol Med Sci"},{"key":"10.1016\/j.phrs.2011.11.017_bib0110","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1124\/jpet.106.105023","article-title":"Expression and transport activity of breast cancer resistance protein (Bcrp\/Abcg2) in dually perfused rat placenta and HRP-1 cell line","volume":"319","author":"Staud","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.phrs.2011.11.017_bib0115","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/095632020601700601","article-title":"Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs","volume":"17","author":"Schang","year":"2006","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.phrs.2011.11.017_bib0120","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3851\/IMP1460","article-title":"The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral properties","volume":"20","author":"Holcakova","year":"2010","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.phrs.2011.11.017_bib0125","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1517\/13543780903418445","article-title":"Seliciclib in malignancies","volume":"18","author":"Aldoss","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.phrs.2011.11.017_bib0130","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1124\/dmd.110.032805","article-title":"ABCB1 transports Seliciclib (R-Roscovitine), a cyclin-dependent kinase inhibitor","volume":"38","author":"Rajnai","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.phrs.2011.11.017_bib0135","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11095-004-9016-0","article-title":"A fluorometric screening assay for drug efflux transporter activity in the blood-brain barrier","volume":"22","author":"Bachmeier","year":"2005","journal-title":"Pharm Res"},{"key":"10.1016\/j.phrs.2011.11.017_bib0140","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11095-008-9738-5","article-title":"Cellular phototoxicity evoked through the inhibition of human ABC transporter ABCG2 by cyclin-dependent kinase inhibitors in vitro","volume":"26","author":"An","year":"2009","journal-title":"Pharm Res"},{"key":"10.1016\/j.phrs.2011.11.017_bib0145","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejphar.2010.07.016","article-title":"Differential inhibition of murine Bcrp1\/Abcg2 and human BCRP\/ABCG2 by the mycotoxin fumitremorgin C","volume":"644","author":"Gonzalez-Lobato","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.phrs.2011.11.017_bib0150","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1074\/jbc.M707773200","article-title":"The 44-kDa Pim-1 kinase phosphorylates BCRP\/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells","volume":"283","author":"Xie","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2011.11.017_bib0155","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.phrs.2011.11.017_bib0160","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/ijc.23938","article-title":"Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model","volume":"124","author":"Appleyard","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.phrs.2011.11.017_bib0165","doi-asserted-by":"crossref","first-page":"5162","DOI":"10.3748\/wjg.14.5162","article-title":"Roscovitine synergizes with conventional chemo-therapeutic drugs to induce efficient apoptosis of human colorectal cancer cells","volume":"14","author":"Abaza","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.phrs.2011.11.017_bib0170","first-page":"273","article-title":"Seliciclib (CYC202; r-roscovitine) in combination with cytotoxic agents in human uterine sarcoma cell lines","volume":"27","author":"Coley","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1016\/j.phrs.2011.11.017_bib0175","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(02)00169-2","article-title":"Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview","volume":"55","author":"Schinkel","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.phrs.2011.11.017_bib0180","doi-asserted-by":"crossref","first-page":"8158","DOI":"10.1158\/1078-0432.CCR-05-1042","article-title":"Roscovitine modulates DNA repair and senescence: implications for combination chemotherapy","volume":"11","author":"Crescenzi","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.phrs.2011.11.017_bib0185","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/1476-4598-9-208","article-title":"R-Roscovitine (Seliciclib) prevents DNA damage-induced cyclin A1 upregulation and hinders non-homologous end-joining (NHEJ) DNA repair","volume":"9","author":"Federico","year":"2010","journal-title":"Mol Cancer"},{"key":"10.1016\/j.phrs.2011.11.017_bib0190","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s10495-011-0583-3","article-title":"Antiapoptotic effects of roscovitine on camptothecin-induced DNA damage in neuroblastoma cells","volume":"16","author":"Pizarro","year":"2011","journal-title":"Apoptosis"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661811002970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661811002970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,19]],"date-time":"2021-12-19T17:09:14Z","timestamp":1639933754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661811002970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S1043661811002970"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2011.11.017","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}